Jump to content

Topics About 'Chronic Bronchitis'.

These are topics that staff believe are closely related. If you want to search all posts for a phrase or term please use the Search feature.

Found 1 result

  1. Meet Ken, a LONHALA MAGNAIR user. Ken, like many people living with COPD, struggled to manage his symptoms with previous treatments. He was motivated to find an option that worked as his disease progressed. For patients like Ken, there’s LONHALA MAGNAIR LONHALA MAGNAIR is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. LONHALA MAGNAIR should not be used as a rescue therapy. Patients should always have a rescue inhaler with them to treat sudden symptoms of COPD. LONHALA MAGNAIR features include: Patients use their natural breathing to take treatment1 Fine, flowing mist administered in 2-3 minutes (with proper assembly and cleaning)1,2* Virtually silent administration3 All within a small, portable, and battery-operated device1† LONHALA vials should only be administered with MAGNAIR. *Improper cleaning and maintenance may increase administration time.1 †Handset is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches. MAGNAIR weighs 10.2 ounces (including batteries).1 How individualizing Ken’s COPD treatment helped him If Ken’s story reminds you of any of your patients, then your go-to devices may not be working for them. According to GOLD (Global Initiative for Chronic Obstructive Lung Disease), the choice of device should be individualized based on patient ability and preferences.4‡ It’s important to note that GOLD does not endorse any specific treatments. While a patient’s preference may be subjective, their ability to use their device can be assessed objectively. Look out for issues, such as, if the patient has5§: Comorbidities that impair their ability to use their device properly Limited inspiratory flow that makes it difficult to inhale the medication Difficulties using the inhaler regardless of how much instruction they are provided The factors listed above could introduce patient errors when administering their treatment.4 It’s important to adjust treatments if you assess that the treatment and/or device doesn’t align with your patient's abilities and preferences.4 Individual results may vary. ‡No randomized trials have identified superiority of one device or formulation.4 §Depending on patient abilities, caregiver assistance may be required for a COPD inhalation device. References: 1. LONHALA MAGNAIR [manufacturer’s instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2019. 2. Pham S, Ferguson GT, Kerwin E, Goodin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162-169. 3. Data on file. PARI. Test report: loudness measurement eLete. November 30, 2017. 4. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020:1-125. 5. Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72. IMPORTANT SAFETY INFORMATION & INDICATION IMPORTANT SAFETY INFORMATION LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients. LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist. As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted. Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy. LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop. The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%). LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair. INDICATION LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. LONHALA and are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license. SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2020 Sunovion Pharmaceuticals Inc. All rights reserved. Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752. 5/20 LON-US-00041-20

This site uses cookies. By using this site, you consent to the placement of these cookies. Read our Privacy, Cookies, and Terms of Service Policies to learn more.